ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Short Interest Update
by Teresa Graham · The Cerbat GemALPS Medical Breakthroughs ETF (NYSEARCA:SBIO – Get Free Report) saw a significant drop in short interest in the month of March. As of March 31st, there was short interest totaling 4,071 shares, a drop of 18.7% from the March 15th total of 5,007 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average daily volume of 31,640 shares, the short-interest ratio is currently 0.1 days.
ALPS Medical Breakthroughs ETF Trading Down 0.5%
Shares of SBIO traded down $0.30 during mid-day trading on Thursday, reaching $56.37. 14,579 shares of the stock traded hands, compared to its average volume of 35,875. The stock has a fifty day simple moving average of $51.42 and a 200 day simple moving average of $48.95. ALPS Medical Breakthroughs ETF has a 12-month low of $25.95 and a 12-month high of $56.72.
Institutional Trading of ALPS Medical Breakthroughs ETF
A number of hedge funds have recently made changes to their positions in SBIO. Jones Financial Companies Lllp bought a new stake in shares of ALPS Medical Breakthroughs ETF in the first quarter worth $782,000. Raymond James Financial Inc. bought a new stake in shares of ALPS Medical Breakthroughs ETF in the second quarter worth $82,000. Moran Wealth Management LLC increased its stake in shares of ALPS Medical Breakthroughs ETF by 72.2% in the third quarter. Moran Wealth Management LLC now owns 17,187 shares of the company’s stock worth $668,000 after buying an additional 7,206 shares during the last quarter. Sterling Investment Advisors Ltd. bought a new stake in shares of ALPS Medical Breakthroughs ETF in the third quarter worth $315,000. Finally, Comerica Bank bought a new stake in shares of ALPS Medical Breakthroughs ETF in the third quarter worth $27,000.
ALPS Medical Breakthroughs ETF Company Profile
The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.